Inhibition of p38 inhibits FOXC2 and reverts prostate cancer cells from a mesenchymal phenotype with metastatic properties to an epithelial phenotype that is incapable of developing metastatic growth [66]. The gene discussed is MAPK14; the disease is prostate cancer.